The working diagnosis is unstable angina, a form of non-ST-segment elevation acute coronary syndrome characterized by acute myocardial ischemia without acute myocardial injury.
The severe ischemic symptoms and objective ischemic ECG abnormalities strongly support acute coronary ischemia. Appropriately timed serial high-sensitivity cardiac troponin measurements do not demonstrate acute myocardial injury, supporting unstable angina rather than NSTEMI. Identification of acute coronary atherothrombosis or another acute coronary pathology on coronary angiography can further confirm the diagnosis.
1. Definition
Unstable angina, or UA, is an acute coronary syndrome characterized by acute myocardial ischemia without detectable acute myocardial injury on appropriately timed contemporary cardiac troponin testing.
Typical presentations include:
1. Angina at rest
2. New-onset severe angina
3. Crescendo angina, with increasing frequency, duration, or severity
4. Angina occurring with progressively less exertion
Unstable angina and NSTEMI are both forms of non-ST-segment elevation acute coronary syndrome, or NSTE-ACS.
NSTEMI is distinguished from unstable angina by the presence of acute myocardial injury together with clinical evidence of myocardial ischemia.
Acute myocardial injury is defined by a rise and/or fall in cardiac troponin with at least one value above the sex-specific 99th percentile upper reference limit.
Acute myocardial injury alone does not establish myocardial infarction because troponin elevation can occur in other conditions, including myocarditis, heart failure, sepsis, renal disease, and tachyarrhythmias. The diagnosis of myocardial infarction requires evidence that the acute myocardial injury is caused by myocardial ischemia.
With widespread use of high-sensitivity troponin assays, unstable angina is diagnosed less frequently than in the past because many patients previously classified as having unstable angina are now identified as having NSTEMI.
2. Etiology
The typical mechanism of atherothrombotic unstable angina is plaque rupture or plaque erosion with superimposed transient or incomplete coronary thrombosis.
2.1 Atherosclerotic Plaque Disruption
The principal mechanisms include:
1. Atherosclerotic plaque rupture
2. Plaque erosion
3. Platelet adhesion and activation
4. Platelet aggregation
5. Thrombin generation
6. Formation of a partially or intermittently occlusive coronary thrombus
7. Distal platelet or thrombotic microembolization in some patients
The degree and duration of ischemia are insufficient to produce detectable acute myocardial injury.
2.2 Other Causes of Acute Coronary Ischemia
Other mechanisms can cause acute ischemic symptoms and should be distinguished from classic atherothrombotic unstable angina.
These include:
1. Epicardial coronary vasospasm
2. Coronary microvascular dysfunction
3. Spontaneous coronary artery dissection
4. Coronary embolism
5. Stimulant-associated coronary vasoconstriction
Severe oxygen supply-demand imbalance caused by conditions such as profound anemia, tachyarrhythmia, hypoxemia, severe hypertension, or thyrotoxicosis should be evaluated separately because the mechanism differs from classic atherothrombotic unstable angina.
3. Pathophysiology
3.1 Plaque Disruption and Thrombosis
1. An atherosclerotic plaque undergoes rupture or erosion.
2. Thrombogenic material is exposed to circulating blood.
3. Platelets adhere, activate, and aggregate.
4. The coagulation cascade generates thrombin and fibrin.
5. A coronary thrombus forms and may partially or intermittently obstruct coronary blood flow.
3.2 Myocardial Ischemia
Reduced coronary perfusion produces an imbalance between myocardial oxygen supply and demand.
The subendocardium is particularly vulnerable to ischemia because of:
1. High intramyocardial pressure
2. Greater wall stress
3. Dependence on diastolic coronary perfusion
Myocardial ischemia may produce:
1. ST-segment depression
2. T-wave inversion
3. Chest pain
4. Transient left ventricular dysfunction
ST-segment depression indicates myocardial ischemia but does not reliably define the anatomic depth or exact location of ischemia.
Certain ST-depression patterns can also represent reciprocal changes from acute coronary occlusion and should therefore be interpreted in the full clinical and ECG context.
3.3 Absence of Acute Myocardial Injury
In unstable angina, ischemia occurs without a diagnostic pattern of acute myocardial injury on contemporary high-sensitivity cardiac troponin testing.
If serial troponin testing demonstrates a rise and/or fall with at least one value above the sex-specific 99th percentile upper reference limit, and there is accompanying evidence of myocardial ischemia, the diagnosis becomes NSTEMI rather than unstable angina.
4. Clinical Features
4.1 Typical Ischemic Symptoms
1. Substernal pressure, tightness, squeezing, heaviness, or discomfort
2. Symptoms occurring at rest or with minimal exertion
3. Prolonged symptoms, often lasting 20 minutes or longer
4. Increasing frequency or severity of previously stable angina
5. New severe angina
4.2 Radiation
Discomfort may radiate to:
1. Left or both arms
2. Shoulder
3. Neck
4. Jaw
5. Back
6. Epigastrium
4.3 Associated Symptoms
1. Dyspnea
2. Diaphoresis
3. Nausea
4. Vomiting
5. Weakness
6. Dizziness
7. Presyncope or syncope
4.4 High-Risk Clinical Features
Features associated with increased risk include:
1. Ongoing or recurrent ischemic chest pain
2. Refractory angina despite medical therapy
3. Hemodynamic instability
4. Acute heart failure
5. Life-threatening arrhythmias
6. Dynamic ST-segment or T-wave changes
7. Transient ST-segment elevation
8. High GRACE risk score
5. Diagnosis
Evaluation of suspected ACS is based on:
1. Clinical history
2. Physical examination
3. 12-lead ECG
4. Serial high-sensitivity cardiac troponin measurements
5. Risk assessment
5.1 Electrocardiography
Possible ECG findings in unstable angina include:
1. Horizontal or downsloping ST-segment depression
2. T-wave inversion
3. Transient ischemic changes
4. A normal or nonspecific ECG
A normal ECG does not exclude ACS.
Dynamic ST-segment or T-wave changes increase the likelihood of an acute ischemic process.
5.2 Important Posterior Occlusion Consideration
ST-segment depression in the anterior precordial leads, particularly V1 through V3, can represent reciprocal changes from posterior coronary occlusion.
Suspicion should increase when anterior ST depression is associated with:
1. Prominent or tall R waves in V1 through V3
2. Increased R/S ratio
3. Upright T waves in the anterior leads
4. Persistent ischemic symptoms
Posterior leads V7 through V9 should be obtained when posterior coronary occlusion is suspected.
In this vignette, the ischemic changes are located predominantly in I, aVL, and V4 through V6, avoiding the classic reciprocal posterior infarction pattern.
5.3 High-Sensitivity Cardiac Troponin
High-sensitivity cardiac troponin is the preferred biomarker for detecting myocardial injury.
Modern accelerated diagnostic pathways use assay-specific algorithms, commonly:
1. 0-hour/1-hour algorithms
2. 0-hour/2-hour algorithms
3. Additional sampling when results remain indeterminate
Important principles include:
1. A single negative troponin obtained very early after symptom onset does not exclude myocardial infarction.
2. Serial measurements must be interpreted according to the specific assay and validated diagnostic pathway.
3. Acute myocardial injury requires a rise and/or fall in troponin with at least one value above the sex-specific 99th percentile upper reference limit.
4. Both absolute troponin concentration and change over time are clinically important.
5. Additional testing is appropriate when a patient remains in an indeterminate observation zone.
In this patient, serial high-sensitivity cardiac troponin measurements remain below the sex-specific 99th percentile upper reference limit without a significant rise or fall, supporting exclusion of acute myocardial injury.
5.4 Echocardiography
Transthoracic echocardiography can assess:
1. Left ventricular systolic function
2. Regional wall motion
3. Mechanical complications
4. Alternative cardiac diagnoses
Echocardiography may be normal in unstable angina.
The absence of regional wall motion abnormalities does not exclude acute coronary ischemia.
5.5 Risk Stratification
Risk assessment helps guide the intensity and timing of treatment.
GRACE Risk Score
The GRACE score estimates mortality risk using clinical variables.
A GRACE score greater than 140 identifies a higher-risk NSTE-ACS population in whom an early invasive strategy is particularly relevant.
TIMI Risk Score for UA/NSTEMI
The traditional TIMI score includes:
1. Age 65 years or older
2. At least 3 coronary artery disease risk factors
3. Known coronary stenosis of at least 50%
4. Aspirin use during the previous 7 days
5. At least 2 anginal episodes during the preceding 24 hours
6. ST-segment deviation of at least 0.5 mm
7. Elevated cardiac biomarkers
The TIMI score may support clinical risk assessment but should not be used in isolation to determine invasive treatment timing.
5.6 Coronary Angiography
Invasive coronary angiography defines:
1. Coronary anatomy
2. Presence and severity of obstructive coronary artery disease
3. Potential culprit lesions
4. Acute coronary atherothrombosis or other coronary pathology
5. Suitability for PCI or CABG
Coronary angiography is not required to form a working clinical diagnosis of unstable angina, but identification of acute coronary atherothrombosis or another acute coronary pathology can confirm the diagnosis.
An invasive strategy during hospitalization is appropriate in patients with intermediate-risk or high-risk NSTE-ACS or a high clinical suspicion of unstable angina.
6. Management
Management should begin while diagnostic evaluation is ongoing when clinical suspicion for ACS is high.
6.1 Initial Measures
1. Rapid assessment of airway, breathing, circulation, and hemodynamic status
2. Prompt 12-lead ECG
3. Continuous cardiac rhythm monitoring
4. Intravenous access
5. Serial high-sensitivity cardiac troponin measurements
6. Assessment of ischemic and bleeding risk
6.2 Aspirin
Aspirin should be administered promptly unless contraindicated.
Recommended loading dose:
162 to 325 mg orally, preferably chewed when feasible
Maintenance therapy generally consists of 75 to 100 mg daily, adjusted according to the antithrombotic strategy.
6.3 P2Y12 Inhibitor Therapy
P2Y12 inhibition is an important component of antiplatelet therapy in confirmed ACS, but the timing depends on the planned invasive strategy.
For NSTE-ACS:
1. In patients undergoing PCI, ticagrelor or prasugrel is generally preferred over clopidogrel when appropriate.
2. Prasugrel is contraindicated in patients with a history of stroke or transient ischemic attack.
3. Clopidogrel is appropriate when ticagrelor or prasugrel is contraindicated, unavailable, or not tolerated.
4. If invasive coronary angiography is planned within approximately 24 hours, routine P2Y12 pretreatment before coronary anatomy is known is not required.
5. If angiography is expected to be delayed beyond approximately 24 hours, pretreatment with clopidogrel or ticagrelor may be considered after balancing ischemic and bleeding risks.
6.4 Anticoagulation
Parenteral anticoagulation is recommended in ACS, with agent selection based on the invasive strategy, renal function, bleeding risk, and local protocol.
Options include:
1. Unfractionated heparin
2. Enoxaparin
3. Fondaparinux in appropriate NSTE-ACS settings
Unfractionated heparin is commonly used when PCI is planned.
Fondaparinux should not be used as the sole anticoagulant during PCI because of the risk of catheter thrombosis.
6.5 Nitrates
Sublingual nitroglycerin can be used for relief of ongoing ischemic chest discomfort when no contraindication is present.
Nitrates should be avoided or used cautiously in:
1. Significant hypotension
2. Suspected right ventricular infarction
3. Recent phosphodiesterase-5 inhibitor use
4. Other conditions in which preload reduction could produce hemodynamic deterioration
Relief of chest discomfort after nitroglycerin is not diagnostic of coronary ischemia.
6.6 Oxygen
Supplemental oxygen is recommended when oxygen saturation is below 90%, or when another clinical indication for oxygen is present.
Routine oxygen is not recommended when oxygen saturation is 90% or greater in the absence of another indication.
Therefore, at an oxygen saturation of 92% on room air, this patient does not require routine oxygen solely because ACS is suspected.
The cause of the relatively reduced oxygen saturation should still be evaluated clinically.
6.7 Beta-Blockers
In patients with ACS without contraindications, an oral beta-blocker should generally be started within the first 24 hours.
Potential contraindications include:
1. Acute decompensated heart failure
2. Low-output state
3. Increased risk of cardiogenic shock
4. Severe bradycardia
5. Significant atrioventricular block without pacing
6. Active severe bronchospasm
Routine aggressive intravenous beta-blockade is not indicated in every patient.
6.8 Lipid-Lowering Therapy
High-intensity statin therapy should be initiated in patients with ACS unless contraindicated.
Examples include:
1. Atorvastatin 40 to 80 mg daily
2. Rosuvastatin 20 to 40 mg daily
This patient has ACS together with multiple major high-risk features, including:
1. Diabetes mellitus
2. Current smoking
3. Hypertension
He therefore meets criteria for very-high-risk ASCVD.
Current secondary-prevention lipid goals are:
1. LDL-C below 55 mg/dL
2. Non-HDL-C below 85 mg/dL
If these goals are not achieved with maximally tolerated statin therapy, additional lipid-lowering therapy should be used.
Options include:
1. Ezetimibe
2. PCSK9 monoclonal antibody therapy
3. Other evidence-based nonstatin therapies when appropriate
6.9 Renin-Angiotensin System Inhibition
An ACE inhibitor or ARB is appropriate in high-risk ACS patients, particularly those with:
1. LVEF 40% or less
2. Hypertension
3. Diabetes mellitus
4. Other appropriate high-risk features
Because this patient has hypertension and diabetes, ACE inhibitor or ARB therapy is appropriate unless contraindicated.
6.10 Proton Pump Inhibitor
A proton pump inhibitor is appropriate in patients receiving antithrombotic therapy who have increased gastrointestinal bleeding risk.
Routine PPI therapy is not required for every patient with unstable angina.
7. Invasive Strategy
The timing of coronary angiography should be determined by clinical risk.
7.1 Immediate Invasive Strategy
Urgent or immediate angiography is indicated when very high-risk features are present, including:
1. Hemodynamic instability or cardiogenic shock
2. Recurrent or refractory chest pain despite medical therapy
3. Life-threatening arrhythmias
4. Cardiac arrest related to the presentation
5. Acute heart failure caused by ongoing ischemia
6. Mechanical complications
7. Recurrent dynamic ischemic ECG changes, particularly intermittent ST-segment elevation
7.2 Early Invasive Strategy
An early invasive strategy, generally within 24 hours, is reasonable in higher-risk NSTE-ACS.
Features supporting an early strategy include:
1. Dynamic ST-segment or T-wave changes
2. Transient ST-segment elevation
3. Confirmed NSTEMI
4. GRACE risk score greater than 140
5. Other significant high-risk clinical features
7.3 Application to This Patient
This patient has:
1. Highly convincing ischemic symptoms
2. Objective ischemic ECG abnormalities
3. Diabetes mellitus
4. Hypertension
5. Hyperlipidemia
6. Active smoking
Despite negative serial troponins, he should not be treated as a low-risk troponin-negative chest-pain patient.
He warrants inpatient cardiology evaluation and an invasive strategy during hospitalization, with timing guided by his clinical risk profile.
8. Revascularization
If coronary angiography identifies significant culprit coronary disease, revascularization may involve:
1. Percutaneous coronary intervention
2. Coronary artery bypass grafting
The choice depends on:
1. Coronary anatomy
2. Disease complexity
3. Diabetes status
4. Left ventricular function
5. Surgical risk
6. Comorbidities
7. Patient preferences
9. Fibrinolytic Therapy
Fibrinolytic therapy is not indicated in unstable angina or NSTEMI.
Fibrinolysis is used in eligible patients with STEMI when timely primary PCI cannot be performed and there are no contraindications.
Suspected acute coronary occlusion without classic ST-segment elevation requires urgent reperfusion evaluation, generally with immediate coronary angiography, rather than automatic fibrinolytic therapy.
10. Secondary Prevention
Long-term management after ACS includes:
1. Smoking cessation
2. High-intensity lipid-lowering therapy
3. Achievement of secondary-prevention lipid targets
4. Blood pressure control
5. Optimal diabetes management
6. Medication adherence
7. Healthy dietary pattern
8. Regular physical activity after clinical stabilization
9. Weight management when appropriate
10. Cardiac rehabilitation
11. Long-term antiplatelet therapy according to ischemic and bleeding risk
In patients without high bleeding risk, dual antiplatelet therapy for approximately 12 months is the default strategy after ACS, with individualized shorter or modified regimens when bleeding risk or other clinical circumstances warrant.
11. Key Clinical Insight
Unstable angina should be considered when there is convincing acute myocardial ischemia but no evidence of acute myocardial injury on appropriately timed serial high-sensitivity cardiac troponin testing.
In this patient, severe resting chest pain, multiple major coronary risk factors, and objective ischemic ECG changes support NSTE-ACS. Serial high-sensitivity cardiac troponin measurements remain below the sex-specific 99th percentile upper reference limit without a diagnostic rise or fall, supporting a working diagnosis of unstable angina rather than NSTEMI.
Identification of acute coronary atherothrombosis or another acute coronary pathology on angiography can further confirm the diagnosis.
References
1. Rao SV, O'Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology. 2025;85(22):2135-2237. doi:10.1016/j.jacc.2024.11.009.
2. Mills NL, Newby LK, Zaman S, et al. Fifth Universal Definition of Myocardial Infarction (2026). Journal of the American College of Cardiology. 2026;88(11):1314-1368. doi:10.1016/j.jacc.2026.07.025.
3. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Journal of the American College of Cardiology. 2026;87(19):2624-2757. doi:10.1016/j.jacc.2025.11.016.
No comments:
Post a Comment